LARIMAR THERAPEUTICS, INC.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-165.7M | $-80.6M | $-36.9M | $-35.4M | $-50.6M | $-42.5M | $-23.1M | $-61.4M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $350.0K | $318.0K | $311.0K | $318.0K | $326.0K | $155.0K | $78.0K | $261.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $7.0M | $8.8M | $7.6M | $6.6M | $5.5M | $2.2M | $129.0K | $9.6M |
| Net Cash from Operating Activities | $-113.2M | $-70.8M | $-33.5M | $-27.6M | $-42.1M | $-42.2M | $-22.7M | $-51.5M |
| Investing Activities | ||||||||
| Capital Expenditures | $91.0K | $515.0K | $164.0K | $100.0K | $333.0K | $62.0K | $83.0K | $108.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $100.3M | $-85.4M | $33.4M | $-91.0M | $24.2M | $17.1M | $-83.0K | $-6.9M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $65.1M | $161.9M | $30.0K | $75.3M | $19.9M | $93.6M | $19.4M | $66.9M |
| Net Change in Cash | $52.2M | $5.7M | $-76.0K | $-43.3M | $1.9M | $68.5M | $-3.4M | $8.6M |
| Free Cash Flow | $-113.3M | $-71.3M | $-33.6M | $-27.7M | $-42.4M | $-42.3M | $-22.8M | $-51.6M |